We gave Halmos one melanoma patient’s exome. It built the pipeline itself then ran it end to end in under two hours.
On the TESLA benchmark, Halmos worked from the raw mutation tables and put a validated epitope in its top twenty for all five patients.
https://t.co/TVuV6k6lJc
The world spends roughly $100 billion a year on experimentation in Life-Science. Yet, 93% of drug programs entering Phase I never reach approval.
Halmos Labs is changing that
See how at https://t.co/iEVkG2oWfj